Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Eastern Cooperative Oncology Group
H. Lee Moffitt Cancer Center and Research Institute
AstraZeneca
NeoImmuneTech
National Cancer Institute (NCI)
Mayo Clinic
OHSU Knight Cancer Institute
M.D. Anderson Cancer Center
University of Wisconsin, Madison
Institut Cancerologie de l'Ouest
Dana-Farber Cancer Institute
AstraZeneca
M.D. Anderson Cancer Center
The Methodist Hospital Research Institute
University of Alabama at Birmingham
Hoffmann-La Roche
I-Mab Biopharma US Limited
Seagen Inc.
Memorial Sloan Kettering Cancer Center
Providence Health & Services
National Institutes of Health Clinical Center (CC)
University of Nebraska
Pfizer
Hoffmann-La Roche
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Gilead Sciences
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Zenith Epigenetics
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
CytoDyn, Inc.
Virginia Commonwealth University
Incyte Corporation
GlaxoSmithKline
Mayo Clinic
Formation Biologics
University of Chicago
Hoosier Cancer Research Network
Numab Therapeutics AG
Thomas Jefferson University
National Cancer Institute (NCI)
Washington University School of Medicine
Baylor Breast Care Center
Providence Health & Services
City of Hope Medical Center
BeiGene